Valneva and Pfizer Report P-II Study (VLA15-221) Results of VLA15 for Lyme Disease in Pediatric and Adolescent
- The company highlighted the positive results from the P-II study (VLA15-221) of VLA15 when given as a booster in pediatric and adolescent patients
- The results showed a strong anamnestic Ab response for all serotypes in pediatric (aged 5-11yrs.) and adolescent patients (aged 12-17yrs.), as well as in adults (aged 18-65yrs.), 1mos. after administration of a booster dose. The safety and tolerability profile of VLA15 after a booster dose was consistent with prior studies
- The vaccine was well-tolerated in all age groups regardless of the primary vaccination schedule with no vaccine-related SAEs and no safety concerns were seen. The company plans to submit BLA to the US FDA and MAA to the EMA in 2026
Ref: Valneva | Image: Valneva
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.